Lululemon Athletica (NasdaqGS:LULU) Q4 2026 Earnings call March 17, 2026 04:30 PM ET Company ParticipantsAndré Maestrini - Interim Co-CEO, President, and Chief Commercial OfficerBrooke Roach - Managing Director of Equity ResearchDana Telsey - CEO and Chief Research OfficerHoward Tubin - VP of Investor RelationsLorraine Hutchinson - Managing DirectorMeghan Frank - Interim Co-CEO and CFOMichael Binetti - Senior Managing DirectorPaul Lejuez - Managing DirectorConference Call ParticipantsAdrienne Yih - Managing ...

Financial Data and Key Metrics Changes - ClearPoint Neuro reported total revenues of $37 million for the year ended December 31, 2025, an increase from $31.4 million in 2024, with $1.2 million attributed to the acquisition of IRRAS Holdings, Inc. [10] - Gross margin for 2025 was 61%, consistent with 2024 [12] - Net cash flows used in operating activities increased to $23.9 million in 2025, up from $8.9 million in 2024 [19] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 10% to $19 million in 2025, up from $17.3 million in 2024, driven by increased product sales [11] - Neurosurgery Navigation revenue grew to $14.8 million in 2025, including $1.2 million from IRRAflow, primarily due to an expanded customer base and the market release of new products [11] - Capital Equipment and Software revenue was $3.1 million for 2025, showing a slight decrease compared to previous periods [12] Market Data and Key Metrics Changes - The company expects revenues for 2026 to be in the range of $52 million to $56 million, reflecting factors such as FDA communications regarding rare diseases and integration efforts from the IRRAS acquisition [8] - The company is targeting a $1 billion market opportunity across four product segments, with expectations for double-digit growth in each segment in 2026 [6][21] Company Strategy and Development Direction - ClearPoint Neuro is focused on developing a complete neuro ecosystem for minimally invasive treatments, including cell and gene therapies [4] - The company has entered two phases of growth strategy: "Fast Forward" to penetrate existing markets and "Essential Everywhere" to build a new market for commercial cell and gene therapy delivery [6][7] - The company aims to achieve 20% market share in a combined $1 billion market opportunity, targeting $200 million in annual revenue [34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position, highlighting a strong foundation built over the past five years with over $100 million invested [5] - The management noted that the company is well-positioned to support biopharma partners in clinical trials and anticipates significant revenue potential from expedited review programs [25] - Management acknowledged challenges related to FDA communications on rare diseases but emphasized a focus on larger patient populations for growth [40][42] Other Important Information - The company has over 60 active biopharma partners and is involved in more than 25 active clinical trials [5] - ClearPoint Neuro's cash and cash equivalents totaled $45.9 million at the end of 2025, up from $20.1 million in 2024, due to proceeds from notes payable and stock offerings [18] Q&A Session Summary Question: Can you elaborate on the 2026 guidance and the impact of recent FDA communications? - Management indicated that guidance was tightened due to more rigorous FDA requirements for rare diseases and the need to reassess integration priorities with IRRAS [38][40] Question: How should we think about organic growth versus growth from IRRAS? - Management expects balanced growth from both organic and IRRAS contributions, with all segments projected to grow in double digits [45][46] Question: What is the pathway from current revenue to $200 million? - Management anticipates a growth rate of 15%-20% as they capture market share across segments, with potential for significant revenue from large GLP studies [49][50] Question: Can you provide details on new partners in expedited review pathways? - Management confirmed new indications and partners, particularly in Parkinson's disease and drug-resistant epilepsy, enhancing confidence in future revenue [60] Question: What is the timeline for expanding into neuro-oncology with Prism? - Management indicated that the timeline for expansion will depend on the strength of their commercial team and ongoing clinical trials [62]

Bob's Discount Furniture (NYSE:BOBS) Q4 2025 Earnings call March 17, 2026 04:30 PM ET Company ParticipantsBill Barton - President and CEOBobby Griffin - Managing Director of Equity ResearchBrad Thomas - Associate Director of ResearchCarl Lukach - EVP and CFOOliver Wintermantel - Managing DirectorPeter Benedict - Managing Director of Equity ResearchConference Call ParticipantsAnthony Chukumba - Managing Director, Senior Research Analyst, and Consumer Sector HeadChristopher Horvers - Senior AnalystMichael Las ...

Bob's Discount Furniture (NYSE:BOBS) Q4 2025 Earnings call March 17, 2026 04:30 PM ET Company ParticipantsBill Barton - President and CEOBobby Griffin - Managing Director of Equity ResearchBrad Thomas - Associate Director of ResearchCarl Lukach - EVP and CFOOliver Wintermantel - Managing DirectorPeter Benedict - Managing Director of Equity ResearchConference Call ParticipantsAnthony Chukumba - Managing Director, Senior Research Analyst, and Consumer Sector HeadChristopher Horvers - Senior AnalystMichael Las ...

Energy Vault (NYSE:NRGV) Q4 2025 Earnings call March 17, 2026 04:30 PM ET Company ParticipantsMichael Beer - CFONoel Parks - Managing Director of Energy ResearchRobert Piconi - Chairman and CEOSid Rajeev - Head of ResearchOperatorPlease note this conference is being recorded. I will now turn the conference over to your host, Michael Beer, Chief Financial Officer. Please go ahead, sir.Michael BeerThank you. Hello, and welcome to Energy Vault's fourth quarter and full year 2025 financial results conference ca ...

Longeveron (NasdaqCM:LGVN) Q4 2025 Earnings call March 17, 2026 04:30 PM ET Company ParticipantsJenny H - Investor RelationsJoshua M. Hare - Co-Founder and CSOLisa Locklear - CFONataliya Agafonova - CMOStephen H. Willard - CEOConference Call ParticipantsBoobalan Pachaiyappan - Managing Director, Senior Biotech AnalystRaghuram Selvaraju - Managing Director, Senior Healthcare AnalystJenny HGood afternoon, everyone, and thank you for joining us today to review Longeveron's 2025 full year financial results and ...

Kestra Medical Technologies (NasdaqGS:KMTS) Q3 2026 Earnings call March 17, 2026 04:30 PM ET Company ParticipantsBrian Webster - President and CEODavid Roman - Managing DirectorNathan Treybeck - VP of Equity ResearchNeil Bhalodkar - VP of Investor RelationsRick Wise - Managing DirectorTravis Steed - Managing Director, Equity Research, and Medical TechnologyVaseem Mahboob - CFOConference Call ParticipantsMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMatthew O'Brien - Sen ...

Trevi Therapeutics (NasdaqGM:TRVI) Q4 2025 Earnings call March 17, 2026 04:30 PM ET Company ParticipantsAlexa Deemer - VP of Biotechnology Equity ResearchBrandon Folkes - Managing Director of Biopharma Biotechnology Equity ResearchDavid Hastings - CFODebanjana Chatterjee - VP of Healthcare ResearchFarrell Simon - Chief Commercial OfficerJames Cassella - Chief Development OfficerJayed Momin - Biopharma Equity Research AssociateJennifer Good - President and CEORyan Deschner - Equity Research AssociateConferen ...

Energy Vault (NYSE:NRGV) Q4 2025 Earnings call March 17, 2026 04:30 PM ET Company ParticipantsMichael Beer - CFONoel Parks - Managing Director of Energy ResearchRobert Piconi - Chairman and CEOSid Rajeev - Head of ResearchOperatorPlease note this conference is being recorded. I will now turn the conference over to your host, Michael Beer, Chief Financial Officer. Please go ahead, sir.Michael BeerThank you. Hello, and welcome to Energy Vault's fourth quarter and full year 2025 financial results conference ca ...

Bob's Discount Furniture (NYSE:BOBS) Q4 2025 Earnings call March 17, 2026 04:30 PM ET Speaker8Thank you, and good afternoon, everyone. Welcome to Bob's Discount Furniture 2025 fourth quarter and full year earnings conference call. At this time, we kindly request that all participants remain in listen-only mode. A question and answer session will follow the formal prepared remarks. As a reminder, this conference call is being webcast live and recorded for replay. On the call today are Bill Barton, President ...